Comment

04.10.17

Accelerating access to treatment and markets

Source: NHE Sep/Oct 17

Hilary Newiss, chair of National Voices, on the latest significant developments of the Accelerated Access Review (AAR) from her perspective as patient champion.

There is some cause for optimism when it comes to implementation of the AAR. 

This autumn we can expect the government’s plan to take forward the recommendations, and we have already seen concrete action. In July, government minister Lord O’Shaughnessy announced up to £86m to support innovators and the NHS in overcoming barriers to getting new, innovative technologies to patients. The funding is a welcome first step towards delivering on the AAR plans. 

Other work is ongoing to build the voice of people and patients into the priority setting for new treatments, and to make the repurposing of drugs more straightforward. 

The National Institute for Health Research is now consulting on best practice for including patients and citizens in all aspects of research and innovation. The need for involvement at every stage of research and innovation was set out in National Voices’ work for the AAR. 

Accelerating or restricting? 

Earlier this year, National Voices convened a workshop of charities and advocacy groups, alongside officials from the Office for Life Sciences. The aim of the meeting was to highlight priority areas for the implementation of the AAR recommendations. However, the discussion was dominated by wider issues of access to treatments and services. 

The positive noises from government on speeding up access to treatment come at a time when measures are being taken to reduce access to services in other areas. For example, the relaxation of the 18-week referral to treatment targets, a consultation on guidance to stop prescribing certain treatments, including those available over the counter, and attempts to avoid paying for specific treatments, such as Pre-exposure prophylaxis (PrEP). You can argue the rights or wrongs of each decision, but taken as a whole, they imply a system restricting access, not accelerating it. 

Of most concern to the national charities at the workshop was the NICE and NHS England decision to implement a new ‘budget impact test’ for new treatments. The new test would mean that roll-out of NICE-approved treatments expected to cost more than £20m in any one of their first three years of use could be delayed for up to three years, or in some cases even longer. 

Many of these measures appear contrary to the notion of accelerating access. 

The benefits of accelerating access 

So how to make sense of these two apparently competing forces? 

When I joined the AAR group in summer 2015 as patient champion, Brexit was not on my mind. In fact, I don’t think I had ever used the word. 

Fast-forward two years and the implementation of the AAR recommendations is increasingly couched in terms of Brexit. Much of the thinking about realising the AAR appears to be focusing on supporting life sciences as part of shaping a post-Brexit economy for the UK. 

The importance of the life sciences industry to the national economy was emphasised by Sir John Bell in his Life Sciences Industrial  Strategy recommendations to government, published in August. Making the UK an attractive place to do business is a reasonable aim, but it is not the only benefit of accelerating access to treatments. 

Improved access to medicines and treatments has the potential to significantly improve the lives of people in the UK. It also has the potential to make the country a more attractive place for the developers of such medicines and treatments, with knock-on benefits for the economy. These benefits are not mutually exclusive; both can be achieved. 

The government must not fall into the trap of seeing the Accelerating Access agenda as solely an issue for the economy. They must retain a focus on the prize of speeding up the roll-out of medicines and treatments that patients and citizens want and need. In doing so, they can improve the lives of people and patients. The aim is to accelerate patients’ access to treatment, as well as companies’ access to markets.

FOR MORE INFORMATION

W: www.nationalvoices.org.uk

Comments

There are no comments. Why not be the first?

Add your comment

 

national health executive tv

more videos >

latest healthcare news

Alexa at forefront of Hancock’s plans for ‘digital transformation’ at NHS

20/07/2018Alexa at forefront of Hancock’s plans for ‘digital transformation’ at NHS

Patients will be able to diagnose symptoms through the use of their Alexa device in a landmark new partnership between the NHS and Amazon. &... more >
Hancock pledges to fix ‘heart-breaking’ low staff morale: ‘I will fight for you’

20/07/2018Hancock pledges to fix ‘heart-breaking’ low staff morale: ‘I will fight for you’

In his first-ever speech since taking up the top job, new health and social care secretary Matt Hancock – who replaces Jeremy Hunt after hi... more >
NHS gets £500m tech boost to overcome ‘binary approach’ to care

20/07/2018NHS gets £500m tech boost to overcome ‘binary approach’ to care

The new health and social care secretary has outlined his plans for the future of the NHS, pledging almost half a billion pounds to the technolog... more >
681 149x260 NHE Subscribe button

the scalpel's daily blog

Personal Health Records: empowering people

18/07/2018Personal Health Records: empowering people

Stewart Fishman, product manager for Personal Health Records (PHRs) at NHS Digital, writes for NHE to discuss the empowering impact PHRs can have for patients. Imagine a future where people can easily choose from a range of secure, usable, online tools to access their care records. They can add information to these tools and share it with anyone involved in their care. It's not too much of a leap, because these tools are available... more >
read more blog posts from 'the scalpel' >

interviews

Duncan Selbie: A step on the journey to population health

24/01/2018Duncan Selbie: A step on the journey to population health

The NHS plays a part in the country’s wellness – but it’s far from being all that matters. Duncan Selbie, chief executive of Pu... more >
Cutting through the fake news

22/11/2017Cutting through the fake news

In an era of so-called ‘fake news’ growing alongside a renewed focus on reducing stigma around mental health, Paul Farmer, chief exec... more >
Tackling infection prevention locally

04/10/2017Tackling infection prevention locally

Dr Emma Burnett, a lecturer and researcher in infection prevention at the University of Dundee’s School of Nursing and Midwifery and a boar... more >
Scan4Safety: benefits across the whole supply chain

02/10/2017Scan4Safety: benefits across the whole supply chain

NHE interviews Gillian Fox, head of eProcurement (Scan4Safety) programme at NHS Supply Chain. How has the Scan4Safety initiative evolved sin... more >

last word

Hard to be optimistic

Hard to be optimistic

Rachel Power, chief executive of the Patients Association, warns that we must be realistic about the very real effects of continued underfunding across the health service. It’s now bey... more > more last word articles >

editor's comment

25/09/2017A hotbed of innovation

This edition of NHE comes hot on the heels of this year’s NHS Expo which, once again, proved to be a huge success at Manchester Central. A number of announcements were made during the event, with the health secretary naming the second wave of NHS digital pioneers, or ‘fast followers’, which follow the initial global digital e... read more >

health service focus